Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 in heart failure with renal dysfunction
ChiCTR1800014308Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan in heart failure (HF), sponsored by Tianjin First Central Hospital. Primary endpoints: B-type natriuretic peptide, creatinine and 2 more. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR1800014308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014308.